Eversept Partners LP Purchases 40,807 Shares of Icon Plc $ICLR

Eversept Partners LP boosted its position in shares of Icon Plc (NASDAQ:ICLR) by 74.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 95,832 shares of the medical research company’s stock after purchasing an additional 40,807 shares during the period. Icon comprises 0.9% of Eversept Partners LP’s holdings, making the stock its 27th biggest holding. Eversept Partners LP’s holdings in Icon were worth $17,463,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in the company. Balyasny Asset Management L.P. bought a new position in Icon during the 4th quarter valued at about $13,763,000. Guggenheim Capital LLC bought a new position in Icon during the 4th quarter valued at about $244,000. AQR Capital Management LLC bought a new position in Icon during the 4th quarter valued at about $308,000. Harris Associates L P boosted its position in Icon by 7.2% in the 4th quarter. Harris Associates L P now owns 2,510,166 shares of the medical research company’s stock valued at $457,402,000 after buying an additional 167,607 shares during the period. Finally, Braidwell LP purchased a new stake in Icon in the 4th quarter valued at about $13,369,000. 95.61% of the stock is currently owned by institutional investors.

Icon Trading Down 0.2%

NASDAQ ICLR opened at $143.27 on Thursday. The company has a quick ratio of 1.10, a current ratio of 1.10 and a debt-to-equity ratio of 0.31. The firm has a market cap of $10.97 billion, a PE ratio of 23.26, a price-to-earnings-growth ratio of 11.34 and a beta of 1.26. The company has a 50 day moving average price of $123.69 and a 200 day moving average price of $139.54. Icon Plc has a 52 week low of $66.57 and a 52 week high of $211.00.

Icon (NASDAQ:ICLR) last posted its quarterly earnings data on Wednesday, June 17th. The medical research company reported $2.52 EPS for the quarter, topping the consensus estimate of $2.47 by $0.05. The firm had revenue of $2.11 billion during the quarter, compared to analyst estimates of $1.99 billion. Icon had a net margin of 5.98% and a return on equity of 9.50%. Icon’s revenue was up 2.5% on a year-over-year basis. During the same quarter in the previous year, the business posted $3.43 EPS. As a group, sell-side analysts forecast that Icon Plc will post 9.74 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on ICLR shares. Leerink Partners set a $145.00 price objective on shares of Icon in a research report on Thursday, May 28th. BMO Capital Markets boosted their price objective on shares of Icon from $130.00 to $160.00 and gave the company an “outperform” rating in a research report on Friday, May 29th. Jefferies Financial Group reissued a “buy” rating and issued a $165.00 price objective on shares of Icon in a research report on Friday, May 29th. Truist Financial boosted their price objective on shares of Icon from $139.00 to $159.00 and gave the company a “hold” rating in a research report on Friday, May 29th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Icon from $120.00 to $130.00 and gave the company a “neutral” rating in a research report on Friday, May 29th. Eight research analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, Icon has a consensus rating of “Hold” and an average target price of $156.44.

Icon Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.